Dystonia-Pipeline Review, H1 2015

Dystonia-Pipeline Review, H1 2015

  • Products Id :- GMDHC6642IDB
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Dystonia-Pipeline Review, H1 2015


Global Markets Direct's, 'Dystonia-Pipeline Review, H1 2015', provides an overview of the Dystonia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dystonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dystonia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Dystonia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Dystonia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Dystonia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Dystonia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Dystonia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Dystonia Overview 6

Therapeutics Development 7

Pipeline Products for Dystonia-Overview 7

Pipeline Products for Dystonia-Comparative Analysis 8

Dystonia-Therapeutics under Development by Companies 9

Dystonia-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Dystonia-Products under Development by Companies 13

Dystonia-Companies Involved in Therapeutics Development 14

Addex Therapeutics Ltd 14

Advicenne Pharma 15

EpiVax, Inc. 16

Ipsen S.A. 17

Medy-Tox Inc. 18

Dystonia-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

abobotulinumtoxin A-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

abobotulinumtoxin A next generation-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ADV-6979-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

dipraglurant ER-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

dipraglurant IR-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

onabotulinumtoxin A-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

onabotulinumtoxin A-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Dystonia-Recent Pipeline Updates 36

Dystonia-Dormant Projects 40

Dystonia-Product Development Milestones 41

Featured News & Press Releases 41

Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia 41

Apr 04, 2014: Medytox Meditoxin(Neuronox) registered in 27 countries worldwide 41

Feb 05, 2014: Ipsen announces clinical results of Dysport Next Generation and its intent to file the first ready-to-use liquid toxin A in Europe and ROW 42

Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 42

Apr 22, 2013: Addex Obtains European Composition Of Matter Patent Covering Dipraglurant And Other mGlu5 Negative Allosteric Modulators 43

Apr 18, 2013: Addex's Dipraglurant Normalizes Striatal Cholinergic Dysfunction In Validated Preclinical Model Of Primary Generalized Torsion Dystonia 1 44

Jan 29, 2013: Addex Therapeutics's Dipraglurant Reduces Motor Abnormalities In Preclinical Model Of Dystonia 45

Feb 26, 2007: Epivax Funded To Advance Research On A New, Improved Botox 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

Number of Products under Development for Dystonia, H1 2015 7

Number of Products under Development for Dystonia-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Dystonia-Pipeline by Addex Therapeutics Ltd, H1 2015 14

Dystonia-Pipeline by Advicenne Pharma, H1 2015 15

Dystonia-Pipeline by EpiVax, Inc., H1 2015 16

Dystonia-Pipeline by Ipsen S.A., H1 2015 17

Dystonia-Pipeline by Medy-Tox Inc., H1 2015 18

Assessment by Monotherapy Products, H1 2015 19

Number of Products by Stage and Target, H1 2015 21

Number of Products by Stage and Mechanism of Action, H1 2015 23

Number of Products by Stage and Route of Administration, H1 2015 25

Number of Products by Stage and Molecule Type, H1 2015 27

Dystonia Therapeutics-Recent Pipeline Updates, H1 2015 36

Dystonia-Dormant Projects, H1 2015 40

List of Figures

Number of Products under Development for Dystonia, H1 2015 7

Number of Products under Development for Dystonia-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 11

Assessment by Monotherapy Products, H1 2015 19

Number of Products by Top 10 Targets, H1 2015 20

Number of Products by Stage and Top 10 Targets, H1 2015 21

Number of Products by Top 10 Mechanism of Actions, H1 2015 22

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Top 10 Routes of Administration, H1 2015 24

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25

Number of Products by Top 10 Molecule Types, H1 2015 26

Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Addex Therapeutics Ltd

Advicenne Pharma

EpiVax, Inc.

Ipsen S.A.

Medy-Tox Inc.

Dystonia Therapeutic Products under Development, Key Players in Dystonia Therapeutics, Dystonia Pipeline Overview, Dystonia Pipeline, Dystonia Pipeline Assessment

select a license
Single User License
USD 2000 INR 142180
Site License
USD 4000 INR 284360
Corporate User License
USD 6000 INR 426540



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com